Keyword Connections

smarca4-deficient nsclc

Journals

0

No Journal Connected

Research Groups

0

No Research Group Connected

Bibliographies

1

1 SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.